Profitelligence Profitelligence · Filing Ledger Open LLY research →

Form 8-K · Current Report · Filed 2026-05-20

Eli Lilly Completes Offering of Multiple Series of Notes

On May 20, 2026, Eli Lilly and Company completed its offering of multiple series of notes, including floating rate and fixed rate notes, totaling approximately $8.94 billion in net proceeds.

Filer
Eli Lilly and Company LLY · NYSE
Filed
Accession
0001193125-26-232707
CIK
0000059478
Signal
Medium impactHealthcare

Details

The notes were issued under an underwriting agreement and an indenture, with specific interest rates and redemption terms. The offering was registered on a Form S-3.

Items reported

Item events

Reported Item

New Debt Issued Financial Instrument Agreement

Market reaction

Close before filing

$1,021.41

Next session

+2.0%

Since filing

+12.5%

Latest close

$1,148.84

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from LLY reporting the same item, with the next session's move:

Insider tape

Within 45 days of this filing, LLY insiders reported 11 Form 4 transactions — net selling of $18.5M.

Full LLY insider history →

About Eli Lilly and Company

Eli Lilly and Company is a renowned pharmaceutical corporation that engages in the discovery, development, manufacturing, and marketing of pharmaceutical products worldwide. The company's core purpose is to create high-quality medications that address significant medical needs in areas such as oncology, immunology, neuroscience, and endocrinology. Eli Lilly is particularly noted for its pioneering work in diabetes care with products like insulin and for its innovative approach to treating complex health conditions. With a history dating back to 1876, the Indianapolis-based company blends scientific innovation with a commitment to improve patient outcomes. Eli Lilly’s role in the financial markets is significant due to its contributions to healthcare advancements and its influence on global pharmaceutical trends. The company's robust pipeline and emphasis on research and development underscore its potential to impact healthcare solutions and deliver sustainable growth. Its products and services are marketed globally, underlying its importance in the biopharmaceutical industry.

Exchange NYSE Industry Drug Manufacturers - General Company website ↗

Never miss another LLY filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts